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ABSTRACT
Though outcomes for pediatric Burkitt lymphoma (BL) have improved significantly
in recent decades with intensive multi-agent chemotherapy and the addition of
rituximab, chemotherapy resistance remains a significant impediment to cure
following relapse. Activation of the PI3K/AKT pathway has been implicated in Burkitt
lymphomagenesis and increased PI3K/AKT activation has been associated with worse
outcomes in adults with aggressive B-cell non-Hodgkin lymphoma (B-NHL). Inhibitors
of the PI3K/AKT pathway have been approved for the treatment of refractory indolent
B-NHL and continue to be investigated for treatment of aggressive B-NHLs. We
investigated the activation of the PI3K/AKT pathway in a cell line model of resistant
BL and the ability to target this pathway with small molecule inhibitors in BL cell
lines. We found that cell lines resistant to rituximab and chemotherapy exhibited
increased activation of PI3K/AKT and that inhibition of AKT or PI3K results in in
vitro anti-lymphoma activity. To investigate the role of PI3K/AKT activation on the
efficacy of cytotoxic chemotherapy, we exposed cells to inhibitors in combination
with chemotherapy and noted a synergistic increase in response to chemotherapy.
Overall these findings highlight the role of PI3K/AKT in chemotherapy resistance in
BL cells and may represent a tractable therapeutic target.

INTRODUCTION

[3–5]. In the small percentage of children who develop
relapsed or refractory disease, the prognosis is much
grimmer with long term survival achieved in only 20–30%
of children following further intensified therapy, generally
including either autologous or allogeneic hematopoietic
stem cell transplant, necessitating the development
of novel therapeutic approaches in an attempt to both
decrease toxicity in up-front therapy and prolong survival
in relapsed/refractory disease [6–9].
Recent publications have reported on genomic
alterations observed in BL which contribute to
lymphomagenesis. Several recurrent abnormalities have

Burkitt lymphoma (BL) is an aggressive form of
B-cell non-Hodgkin lymphoma (NHL) and is the most
common type of NHL in children. With intense, multiagent chemotherapy regimens, survival rates for childhood
BL have improved significantly in recent decades.
Currently, greater than 90% of children diagnosed with
BL are cured of their disease [1, 2]. While highly curable,
the therapy is quite toxic with high rates of acute toxicity
including mucositis and infections. Approximately 2% of
children with BL die from toxic complications of therapy
www.oncotarget.com
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RESULTS

been described by our group and others [10–12]. Schmitz
et al identified genomic abnormalities in sporadic BL cases
and cell lines [13]. Compared to tumor cells from germinal
center B-cell (GCB) derived diffuse large B-cell lymphoma
(DLBCL), BL tumors harbor recurrent mutations that were
distinct from those seen in GCB DLBCL. Along with
the expected mutation of the C-MYC proto-oncogene,
additional recurrent mutations were observed in in the gene
encoding TCF3 and that of its negative regulator ID3 with
up to 70% of tumors bearing mutations in one or both of
the genes suggesting TCF3 may play a vital role in BL
lymphomagenesis. This was further supported by the lethal
effects of TCF3 knockdown or ID3 wildtype overexpression
in BL cell lines. TCF3 was noted to upregulate components
of the B-cell receptor (BCR) pathway leading to activation
of the phosphatidylinositol-3-kinase (PI3K) pathway
through “tonic” non-NF-kB dependent BCR signaling,
rather than the NF-kB dependent chronic active BCR
signaling seen in activated B-cell like (ABC) DLBCL,
potentially through its effects on the phosphatase SHP-1
which inhibits BCR signaling. Additional data supporting
the relevance of the PI3K pathway to BL lymphomagenesis
was reported in a recently developed transgenic mouse
model and in a proteomic analysis reported by our group
[14, 15]. In this model, concurrent activation of both
c-Myc and PI3K was noted to lead to lymphoid tumors that
morphologically and genetically appear BL-like suggesting
the coordination of overexpression of Myc and activation of
PI3K may contribute to development of BL.
Overexpression of Myc may further contribute to the
activation of PI3K through the Myc dependent induction of
microRNAs (miRs) associated with PI3K activation through
their inhibitory effect on PTEN, in particular the miR1792 cluster [16, 17]. Increased expression of Myc-induced
miRs has been linked to increased relapse risk in childhood
BL. A genome wide copy number analysis of childhood
BL samples identified a recurrent gain in the region of
13q31, which incorporates the MIR17HG locus [18]. These
samples had higher expression of miR-17 and tended toward
early relapse. These findings were further validated by a
second report associating increased expression of miR-17
with shorter overall survival (OS) [19].
With the apparent importance of c-Myc and PI3K
coordination in BL lymphomagenesis, we investigated
the activity of inhibitors of the PI3K/Akt/mTOR pathway
in BL cell lines. Numerous inhibitors of this pathway
are in clinical development including both narrowly and
broadly focused inhibitors in addition to dual inhibitors
of both PI3K and mTOR. The more targeted inhibitor
of the delta isoform of PI3K, idelalisib, has already
gained regulatory approval for the treatment of relapsed
chronic lymphocytic leukemia (CLL), small lymphocytic
lymphoma (SLL) and follicular lymphoma (FL). In our
current contribution, inhibition of the PI3K/Akt/mTOR
pathway was investigated in a panel of BL cell lines
including cell lines that exhibit a high degree of resistance
to both chemotherapy and anti-CD20 immunotherapy.
www.oncotarget.com

With reported evidence of increased Akt activation
having a potential impact on survival in B-cell NHL
[20–23], we initially characterized the Akt activation in
our sensitive and resistant Raji cell lines. On Western blot
analysis of p-Akt expression, rituximab-chemotherapy
sensitive Raji cells exhibited lower p-Akt expression
when compared to the rituximab-chemotherapy resistant
Raji 2R and Raji 4RH cell lines (Figure 1A). Similar
findings were observed using phospho-flow cytometry,
where an approximately 2 fold increase in p-Akt was
observed in the resistant Raji cell lines (Figure 1B and
Supplementary Figure 1). In order to further evaluate the
activation of Akt in these cell lines, the phosphorylation
status of downstream targets of Akt was also determined
using Western blotting (Supplementary Figure 2). In the
resistant cell lines, multiple targets of Akt demonstrated
a pattern of increased phosphorylation in the resistant
cell lines (Figure 1C). Additionally, in a previously
reported phosphoproteomic analysis of parental Raji
cells compared to rituximab-chemotherapy resistant Raji
4RH cells, the B-cell receptor pathway was one of the top
pathways with significant differential phosphorylation
including differential phosphorylation of several proteins
both up and downstream of PI3K and Akt associated with
PI3K/Akt pathway activation (Figure 1D). These findings
indicated a possible role of increased activation of the
PI3K/Akt/mTOR pathway in the chemotherapy resistance
observed in our resistant BL cells suggesting that targeting
this pathway may be therapeutically relevant in BL.
With Akt being central to activity of the PI3K/Akt/
mTOR pathway, we initially investigated the effect of
direct Akt inhibition with the pan-Akt inhibitor MK-2206.
Burkitt cell lines were exposed to MK-2206 over a range
of concentrations and durations. Direct inhibition of Akt
by MK-2206 resulted in a decrease in cellular proliferation
exhibited in AlamarBlue assays of cell viability compared
to control (Figure 2). While a decrease in cell proliferation
was observed, determination of apoptosis induction
by western blot for cleaved PARP indicated that Akt
inhibition by MK-2206 was not leading to significant
apoptosis induction as a single agent in any of the Raji
cell lines; though a modest increase in PARP cleavage
was noted in Ramos cells indicating that this was likely a
primarily anti-proliferative effect (Figure 3A).
In order to investigate the hypothesis that
PI3K/AKT/mTOR pathway activation contributes to
chemotherapy resistance, we investigated targeting
AKT either via siRNA knockdown or with MK-2206 in
combination with chemotherapeutic agents (Figure 3).
Following AKT knockdown, cells were resuspended
in fresh medium and cell proliferation and viability
were determined after 72 hours using Trypan blue. A
decrease in cell proliferation and viability was noted in
knockdown cells as compared to cells transfected with
a control scramble siRNA. This was particularly noted
21821
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in the Raji 4RH cells with a decreased number of cells
(scramble vs siRNA: 0.41 × 106 vs 0.12 × 106 cells/mL)
and viability (82% vs 62%). Following demonstration of
Akt knockdown by Western blot, an Alamar Blue assay
was performed after 48 h of incubation with doxorubicin.
In Raji Akt KD cells, a modest increase in response to
doxorubicin was noted with a decrease in viability of
KD cells compared to controls (27% vs 19%, p < 0.03)
(Figure 3A). When BL cell lines were exposed to both
MK-2206 and chemotherapy, significant increases in
chemotherapy activity were noted. In particular, the
combination of MK-2206 with doxorubicin (CI values
0.4–0.7) (Figure 3C) or dexamethasone (CI values 0.3–0.8)
(Figure 3D) resulted in significant synergistic reductions in
viable cells in AlamarBlue assays when compared to either
single agent exposure after normalization to vehicle treated
control, as determined using the Chou-Talalay method.
Additionally, while single agent MK2206 exposure did not
result in significant induction of apoptosis as measured by
western blot for PARP cleavage, a synergistic increase in
cleaved PARP was noted in combinations of MK-2206 and
doxorubicin in both Raji and Ramos cell lines (Figure 3B).
In the resistant Raji 4RH cells, however, there was still no
significant indication of apoptosis induction. This is likely
related to the highly impaired apoptotic machinery in these
resistant cell lines, also previously described.

To further investigate the role of PI3K/Akt/
mTOR pathway inhibition in BL, additional experiments
were performed with the PI3K-delta isoform specific
inhibitor idelalisib, which is already FDA approved for
relapsed/refractory CLL/SLL and FL. Similar to MK2206, a decrease in BL cell viability was noted with
increasing concentrations of idelalisib while Idelalisib
exposure also resulted in dose-dependent cell cycle
arrest leading to a significant accumulation of cells
primarily in G1, though with significant G2/M arrest
also noted in resistant Raji 4RH cells (Figure 4C and
Supplementary Figure 3). The concentrations required
to achieve activity in the BL cell lines tested was well
into the μM range with IC50 concentrations ranging
from 50–300 μM after a 48 h exposure (Figure 4A). At
concentrations at or exceeding the IC50 concentration,
idelalisib did result in induction of apoptosis in all
cell lines, though to a significantly lesser degree in the
resistant Raji 4RH cells (Figure 4B and Supplementary
Figure 4). Inhibition of PI3K-delta with idelalisib inhibited
downstream pathway activation as exhibited by decreases
in the phosphorylation of downstream targets including
pS6 and pGSK3B by western blotting (Figure 4D).
Though idelalisib required high concentrations to
demonstrate single agent anti-proliferative activity,
lower concentrations of idelalisib when combined with

Figure 1: Chemotherapy resistant BL cell lines exhibit an increase in Akt activation. Raji 2R and Raji 4RH cell lines derived

from the BL Raji cell line demonstrate an increase in Akt phosphorylation by (A) Western blot and (B) phosphoflowcytometry indicating
increased activation of the PI3K/Akt pathway. (C) Proteins up and downstream from AKT in the B-cell receptor and PI3K/AKT pathways
are differentially phosphorylated in Raji 2R and Raji 4RH cells compared to parental Raji cells on Western blotting. (D) Phosphoproteomic
analysis identified the B cell receptor signaling pathway as one of the top differentially phosphorylated pathways in Raji 4RH cells with
several targets of AKT exhibiting increased phosphorylation. Error bars represent 95% confidence intervals. (^P-value < 0.03).
www.oncotarget.com
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Figure 2: Inhibition of Akt by the inhibitor MK-2206 leads to a decrease in cellular viability in a panel of BL cell lines.

(A) The BL cell lines Raji, Raji 2R, Raji 4RH, Ramos and Daudi were exposed to escalating concentrations of MK2206 for 48 hours and
exhibited a dose dependent decrease in viable cells. (B) IC50 concentrations at 48 hours. Error bars represent 95% confidence intervals.

Figure 3: Knockdown of AKT or inhibition of AKT by MK2206 leads to an increase in response to cytotoxic
chemotherapy. (A) Akt knockdown by siRNA led to a decrease in Raji cell viability following 48 hour exposure to doxorubicin. (B) BL
cell lines were exposed to MK2206 alone or in combination with doxorubicin for 48 hours and apoptosis was measured by Western blot
for cleaved PARP. Raji and Ramos cells exhibited little apoptosis following exposure to MK2206 alone however a synergistic increase in
PARP cleavage was noted with the combination treatment. In vitro exposure to MK2206 and (C) doxorubicin or (D) dexamethasone leads
to a synergistic decrease in cell viability in BL cell lines. Error bars represent 95% confidence intervals. (^p < 0.05. M = MK2206, D =
Doxorubicin, Dex = Dexamethasone).
www.oncotarget.com
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dexamethasone led to a synergistic induction of apoptosis,
in particular in the relatively more sensitive Ramos and
Daudi cell lines (Figure 5A and Supplementary Figure 5).
Western blots also demonstrated a synergistic induction
of PARP cleavage in Raji cells treated with idelalisib and
dexamethasone (Figure 5B). This correlated with changes
in expression of Bcl-2 family proteins including an increase
in pro-apoptotic Bax and Bak and a decrease in antiapoptotic MCL-1 leading to an overall more pro-apoptotic
pattern of Bcl-2 family protein expression (Figure 5C).

Inhibitors of this pathway continue to be investigated in
adult lymphoma with most success noted in more indolent
lymphoma sub-types. Activity of idelalisib in adults with
DLBCL has been very limited.
In our preclinical testing, we demonstrated that, in
our cell line model of resistant BL, the PI3K/AKT/mTOR
pathway appears to exhibit increased activation. Targeting
either AKT or PI3K with pharmacological inhibitors led to
primarily an anti-proliferative effect in a panel of Burkitt cell
lines with the majority of activity noted at concentrations
in the high μM range. In general these concentrations
exceed the peak plasma concentrations noted in phase
1 pharmacokinetic studies of these agents in humans
[28, 29]. This limited in vitro activity at biologically relevant
concentrations may relate to the lack of activity noted in
single agent trials of idelalisib in aggressive B-cell NHLs.
However, at concentrations below those leading to
single agent activity, there was noted to be an increase in
apoptosis induction in response to chemotherapy exposure
in combination with inhibition of AKT or PI3K. In a report

DISCUSSION
BL is an aggressive form of B-NHL that is
highly curable with intensive multi-agent chemoi
mmunotherapeutic regimens [24–26]. Our group and
others have reported that recurrent genetic abnormalities
have been observed in children with BL including the
critical importance of the PI3K/Akt/mTOR pathway
in Burkitt lymphomagenesis [10, 12–14, 18, 19, 27].

Figure 4: Inhibition of PI3K-delta isoform by idelalisib leads to decreased proliferation and induction of apoptosis in
BL cell lines. (A) In vitro exposure to idelalisib for 24 or 48 hours leads to a dose- and time-dependent decrease in BL cell viability and

(B) induction of apoptosis after 48 hours of exposure. (C) Decreased proliferation is associated with an arrest in G1 or G2/M phase of the
cell cycle after a 48 hour exposure to idelalisib. (D) Idelalisib exposure leads to decreased phosphorylation of downstream targets. Error
bars represent 95% confidence intervals. (*p < 0.01, ^p < 0.05).
www.oncotarget.com
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from the Bonavida laboratory, the PI3K/Akt pathway was
previously noted to be involved in chemosensitization
observed following exposure of BL cell lines to the antiCD20 monoclonal antibody rituximab [30]. While this
previous report implicated a decrease in the anti-apoptotic
Bcl-xL protein, we did not observe such a decrease
following PI3K inhibition with idelalisib, though we did
note changes in expression of other Bcl-2 family proteins
including the pro-apoptotic Bax and Bak proteins likely
leading to a similar alteration in apoptotic potential
following PI3K inhibitor exposure [31]. The possible
contribution of increased AKT activation to resistance to
rituximab in DLBCL has also been suggested [32]. The
interaction of BCL-2 family regulators of apoptosis and
activity of the PI3K/AKT/mTOR pathway has been further
highlighted by the synergistic activity of BH3 mimetic
agents in combination with inhibition of the PI3K/
AKT/mTOR pathway with findings of altered MCL-1
and BAX expression following inhibition of PI3K/AKT/
mTOR, similar to our results reported here, associated
with increased activity of the BCL-2 inhibitor ABT-199
[31, 33, 34]. Additionally, the PI3K/Akt/mTOR pathway
has been reported to play a central role in the activity of

a variety of targeted therapeutic agents under pre-clinical
investigation in aggressive B-cell NHL, in many cases
through alterations in BCL-2 family protein expression
[35–38].
While single agent inhibition of PI3K has
demonstrated promise in targeting B-NHL, the
investigation of agents targeting the PI3K/AKT/mTOR
pathway with enhanced activity has also led to the
development of numerous inhibitors more broadly
targeting PI3K (compared to the delta isoform specific
idelalisib) or targeting both up- and down-stream targets
in the pathway, such as through dual targeting inhibitors of
PI3K and mTOR. Such agents have exhibited pre-clinical
and clinical activity expanding the repertoire of agents
targeting this pathway [39–43].
Though PI3K inhibitors have led to limited single
agent activity in aggressive adult B-cell lymphomas,
considering the data suggesting synergistic activity of
PI3K/AKT/mTOR inhibition, a more rational application
may be in the setting of combination therapy along
with cytotoxic chemotherapy or other targeted agents.
A potential area of concern in regards to the use of
agents targeting this pathway is an apparent high rate of

Figure 5: Exposure to idelalisib increases induction of apoptosis in response to cytotoxic chemotherapy. (A) BL cells
exposed to idelalisib and dexamethasone for 48 hours exhibit synergistic induction of apoptosis as measured by flow cytometry for
Annexin V and propidium iodide staining in BL Ramos and Daudi cells, but no apoptosis induction in Raji or Raji 4RH cells in vitro.
(B) PI3K inhibition by idelalisib leads to synergistic induction of PARP cleavage when combined with dexamethasone in Raji cells and
when combined with dexamethasone or doxorubicin in Daudi cells. (C) Idelalisib exposure leads to altered expression of Bcl-2 family
regulators of apoptosis. (Dex = Dexamethasone, Dox = Doxorubicin).
www.oncotarget.com
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toxicities, including potentially serious gastrointestinal,
hepatic and pulmonary toxicities, that have been observed
in adult patients being treated with idelalisib or the
Bruton’s tyrosine kinase inhibitor ibrutinib, in particular
when utilized in combination with other therapeutic
agents [44, 45]. This may impair the ability to combine
these agents with the types of chemotherapy agents
typically used in treating BL. Additionally, despite the
dismal prognosis for such patients, the rarity of childhood
relapsed/refractory BL along with the sheer number of
available agents currently under investigation in adults
(including numerous agents targeting the PI3K/Akt/mTOR
pathway) complicates the choice of which agents to pursue
clinically, making the establishment of biological rationale
critical to future clinical investigation of novel therapies in
pediatric B-NHL.
In summary, targeting PI3K appears to have
biological relevance in BL and in vitro targeting of the
PI3K/Akt/mTOR pathway in models of BL exhibits
promising pre-clinical activity validating further pursuit
of novel therapeutic agents targeting this pathway in
BL. Though initial clinical trials of idelalisib in adults
with DLBCL have been less promising, the activity of
narrow versus broad inhibition of PI3K, further upstream
inhibition with inhibitors of the B-cell receptor or dual
inhibition of both up and downstream targets within the
pathway also continue to be investigated and may hold
additional promise of clinical efficacy, while observed
toxicity continues to be a potential limiting factor to
incorporation of these agents to the intense chemotherapy
regimens generally used in treating aggressive childhood
B-NHLs and needs to be further characterized.

(Bedford, OH, USA) and dexamethasone was provided by
the Roswell Park Cancer Institute (RPCI) Pharmacy.
Primary mouse anti-human antibodies raised
against BAK, BAX, BCL-XL, MCL-1, PARP, AKT,
p-AKT, GSK3B, p-GSK3B, S6, p-S6, PDK1, p-PDK1,
p27, p21, BAD, p-BAD, 4-EBP1, p-4-EBP1 and actin
were purchased from Cell Signaling Technologies
(Danvers, MA, USA). Alkaline phosphatase (AP)
or horseradish peroxidase (HRP) conjugated antimouse secondary antibodies were purchased from
Jackson ImmunoResearch (West Grove, PA, USA).
Ficoll-Hypaque was purchased from Sigma-Aldrich
Inc. (St. Louis, MO, USA). Sodium chromate51 (51Cr)
(Perkin-Elmer Life Inc., Boston MA) was utilized in
immunological assays assessing antibody-dependent
cellular cytotoxicity (ADCC) and complement mediated
cytotoxicity (CMC). Triton X-100, trypan blue and
histopaque-1077 were obtained from Sigma-Aldrich Inc.
(St Louis, MO). Cell Titer-Glo Luminescent Viability
Assay reagent was purchased from Promega (Madison,
WI, USA). PrestoBlue cell proliferation assay reagent
was purchased from (Invitrogen, Grand Island, NY,
USA). AKT siRNA (ON-TARGET plus Smart Pool
siRNA) was purchased from Dharmacon (Lafayette,
CO, USA).

Transient siRNA AKT knockdown
A transient AKT siRNA knockdown was performed
in Raji and Raji 4RH cells. Cells were cultured in
RPMI1640 with 10% HIFBS at 37° C in 5% CO2. Cells
were passaged 3 days before experimental start and in
log rhythmic growth phase. 2 × 106 cells were pelleted,
washed and combined with 100uL Amaxa Nucleofector
Solution (Lonza, Walkersville MD, USA) and then
transferred to an Amaxa cuvette where siRNA was added
at a concentration of 300 nM/sample. Samples were then
electroporated using Amaxa Nucleofector Devise (Lonza,
Walkersville MD, USA) using the M-13 protocol. After
electroporation cells were transferred back into media and
allowed to recover and presence of siRNA knockdown
was detected via western blot.

MATERIALS AND METHODS
Cell lines and culture
BL cell lines were used for the experiments
including Raji, Ramos and Daudi and were purchased
from American Type Culture Collection (ATCC,
Manassas, VA, USA). Rituximab resistant cell lines Raji
2R and Raji 4RH were created and characterized from
parental Raji cells as previously described [46, 47]. All
cell lines were maintained in RPMI 1640 with Glutamax-1
(Invitrogen, Karlsruhe, Germany) supplemented with
10% heat-inactivated fetal bovine serum (FBS), HEPES
(5 mmol/l), penicillin and streptomycin at 100 IU/ml and
sodium pyruvate 1 mmol/l.

Phosphoproteomic analysis
Mass spectrometry-based label-free quantitative
phosphoproteomic profiling of the BL cell lines Raji
and Raji4RH was performed as previously described
[48, 49]. Briefly, six milligrams of protein from each cell
line were digested by trypsin and peptides were subjected
to phosphopeptide enrichment using metal oxide affinity
chromatography (MOAC) and immunoprecipitation. An
LTQ Orbitrap XL in-line with a Paradigm MS2 HPLC
was employed for acquiring high-resolution MS and MS/
MS data that were searched with the Swissprot Human
taxonomic protein database.

Reagents and antibodies
The AKT inhibitor (MK-2206) and the PI3Kdelta inhibitor (idelalisib) were purchased from Selleck
Chemicals (Houston, TX, USA). Cisplatin was purchased
from American Pharmaceutical Partners (Schaumburg,
IL, USA). Doxorubicin was obtained from Bedford Labs
www.oncotarget.com
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Changes in expression of PI3K/Akt target proteins
and Bcl-2 family members by Western blot

Louis, MO, USA). Briefly, cells were exposed idelalisib
(1, 10, 50 or 100 μM) or DMSO control for 48 hours and
subsequently harvested, washed three times in PBS, fixed
in 70% ethanol for 30 minutes on ice and then incubated
in a PBS/ribonuclease solution for 30 minutes at 37° C
(1mL PBS & 10 μM ribonuclease). Data was collected
on a FACSCalibur flow cytometer (BD Biosciences; San
Jose, CA, USA) and analyzed with Mod Fit LT Version 3.2
software (Verity Software House, Topsham, ME, USA).
Results represent the mean value of three independent
experiments.

Following relevant drug exposure to PI3K/Akt
inhibitors for 24 hours, cells were lysed with a RIPA
buffer containing 2 mM PMSF, 1 μg/ml of leupeptin,
1 μg/ml pepstatin and 1 μg/ml aprotinin. After
solubilization at 4° C × 60 minutes, nuclei and debris
were pelleted at 10,000 rpm for 30 minutes. Protein was
quantified using Opsys MR (Thermo LabSystems Inc.,
Beverly, MA, USA). Lysates were prepared with equal
amount of protein, distilled water and 4× laminar buffer.
Lysate was loaded onto a 12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) gel and
transferred onto a nitrocellulose membrane using iBLOT
(Invitrogen Technologies, Grand Island, NY, USA). The
membrane was blocked for a minimum of 1 hour with
5% milk in PBS and then incubated at 4° C overnight
with antibodies directed against proteins of interest. After
adding the appropriate AP- or HRP-conjugated secondary
antibody, detection was performed using enhanced
chemiluminescence visualization system (ECL, plus,
Amersham Life Sciences, Arlington Heights, IL, USA).
Western blots were performed on three occasions and
representative results are depicted.

Determination of apoptosis induction in BL cell lines
exposed to MK2206 or idelalisib
Cell lines were exposed to MK2206 or idelalisib for
48 hours in a 6 well plate at 0.5 × 106 cells/ml. Apoptosis
was analyzed using Western blotting (as above) using
anti-PARP antibody and/or flow cytometry by Annexin
V-propidium iodide staining.

Statistics
Graphic analysis was performed using IBM SPSS
21. Significance was determined using a student’s T test.
Synergy in combination experiments was determined
by the Chou-Talalay method using CalcuSyn software
and reported as Combination Index (CI) with values
<0.9 indicating synergy and values >1.1 indicating
antagonism.

In vitro effects of PI3K pathway inhibition on the
viability of BL cell lines
Cell lines were exposed to escalating doses of MK2206 (1–50 uM) or idelalisib (0.1–400 μM) or vehicle
control (DMSO) for 48 hours. Cells were plated at a cell
density of 0.25 × 106 cells/ml in 96 or 384 well plates and
at each time period 20 μL of Alamar blue was added to
each well and then incubated for 2 additional hours. Cell
proliferation was determined as the change in Alamar blue
reduction by living cells and measured using a Fluoroskan
Ascent LF (Thermo Fisher Scientific, Barrington, IL, USA).
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